Engineered immune cells take on tough T-Cell cancers
NCT ID NCT06316427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The goal is to check safety and see how well the treatment works in 80 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
-
Shanghai Liquan Hospital
RECRUITINGShanghai, Shanghai Municipality, 201418, China
-
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITINGChengdu, Sichuan, 610083, China
-
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine
RECRUITINGShanghai, Shanghai Municipality, 200435, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we make CAR-T cells last longer in leukemia?
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at tough childhood leukemia
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL